Group 1 - The core viewpoint of the news highlights the strong performance of the innovative drug sector in the first half of the year, driven by successful collaborations, excellent clinical data, and supportive policies [1] - The China Securities report indicates that the innovative drug sector is expected to see a rapid increase in the commercial value of newly launched products due to national policies encouraging innovation [1] - The proportion of domestic innovative drugs in hospital products is anticipated to rise quickly, positioning this sector as one of the best growth segments [1] Group 2 - The index focuses on leading innovative drug companies in the A-share market, consisting of no more than 50 stocks involved in innovative drug research and development [4] - The index has shown a rolling price-to-earnings ratio of 59.2 times and an increase of 91.3% since its inception [5] - The biotechnology ETF tracks the China Biotechnology Theme Index, which includes up to 50 stocks related to gene diagnostics, biopharmaceuticals, and other human biotechnology [6] Group 3 - The healthcare ETF tracks the CSI 300 Healthcare Index, covering leading companies in the healthcare sector, including chemical pharmaceuticals, medical services, and medical devices [8] - The CSI 300 Healthcare Index has a rolling price-to-earnings ratio of 33.9 times and has increased by 65.7% since its inception [9]

Group 1 - The core indices related to the Hong Kong and A-share pharmaceutical sectors have shown significant increases, with the CSI Hong Kong Stock Connect Healthcare Index rising by 5.1%, the Hang Seng Stock Connect Innovative Drug Index by 4.8%, the CSI Innovative Drug Industry Index by 4.6%, the CSI Biotechnology Theme Index by 4%, and the CSI 300 Healthcare Index by 3.6% [1][5][9][13][15] - The Hang Seng Innovative Drug ETF (159316) has seen continuous capital inflow for four consecutive trading days, with its latest scale exceeding 1.8 billion yuan, marking a historical high [1] Group 2 - The CSI Hong Kong Stock Connect Healthcare Index focuses on leading stocks in the Hong Kong healthcare sector, comprising 50 stocks from medical devices, biopharmaceuticals, chemical drugs, and other healthcare-related companies [3] - The CSI Innovative Drug Industry Index targets leading innovative drug companies in the A-share market, consisting of no more than 50 stocks involved in innovative drug research and development [7] - The CSI Biotechnology Theme Index centers on leading biotechnology companies in the A-share market, including no more than 50 stocks related to gene diagnosis, biopharmaceuticals, blood products, and other human biotechnology [11] - The CSI 300 Healthcare Index encompasses leading companies in the A-share healthcare sector, covering chemical pharmaceuticals, medical services, medical devices, and other segments of the future health industry [15]

截至收盘，恒生港股通创新药指数上涨2.4%，中证港股通医药卫生综合指数上涨2.1%，中证创新药产业指数上涨0.4%，中证生物科技主题指数上涨0.2%， 沪深300医药卫生指数上涨0.1%。Wind数据显示，恒生创新药ETF（159316）半日获3500万份净申购，截至昨日，该产品已连续15个交易日获资金加仓。 组成。 创新药ETF易方达得 跟踪中证创新药产业指数 该指数聚焦A股创新药龙头, 截至午间收盘 该指数 由不超过50只主营业务涉 该指数涨跌 滚动市盈率 及创新药研发的公司股票 组成,汇聚A股创新药主力 0.4% 53.9倍 军。 生物科技ETF (00) 跟踪中证生物科技主题指数 该指数聚焦A股生物科技龙 头,由不超过50只业务涉 及基因诊断、生物制药、血 液制品及其它人体生物科技 的公司股票组成。 截至午间收盘 该指数 该指数涨跌 滚动市盈率 0.2% 56.4倍 医药ETF ONLY 跟踪沪深300医药卫生指数 （文章来源：每日经济新闻） ...